title: [Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid].
abstract: The biological agent cetuximab specifically inhibits the epidermal growth factor receptor (EGFR) function. Cetuximab is licensed for treatment of metastatic colorectal carcinoma, as it enhances the efficacy of cytostatic therapy. Acneiform drug eruptions are common side effects. We report two patients with metastatic colorectal carcinoma, who developed a severe acneiform drug eruption on the face and upper part of the body during the treatment with cetuximab. Triple therapy consisting of systemic isotretinoin, topical nadifloxacin and topical corticosteroid produced rapid improvement with moderate cheilitis the only side effect. We conclude that triple therapy is an effective treatment for patients with severe acneiform drug eruptions caused by cetuximab.
authors.affiliation: Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität München, Frauenlobstrasse 9-11, 80337 Münich, Germany. andreas.wollenberg@lrz.uni-muenchen.de
authors.forename: A
authors.initials: A
authors.lastname: Wollenberg
authors.forename: N
authors.initials: N
authors.lastname: Moosmann
authors.forename: J
authors.initials: J
authors.lastname: Kroth
authors.forename: V
authors.initials: V
authors.lastname: Heinemann
authors.forename: E
authors.initials: E
authors.lastname: Klein
mesh_terms: D017486:Acneiform Eruptions / Q000139:chemically induced* / Q000188:drug therapy*; D000284:Administration, Oral; D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000556:secondary; D003879:Dermatologic Agents / Q000008:administration & dosage*; D003875:Drug Eruptions / Q000188:drug therapy* / Q000209:etiology*; D004359:Drug Therapy, Combination; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D024841:Fluoroquinolones / Q000008:administration & dosage*; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011807:Quinolizines / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D003879:Dermatologic Agents; D024841:Fluoroquinolones; D011807:Quinolizines; C062127:nadifloxacin; D066246:ErbB Receptors; D015474:Isotretinoin; D000068818:Cetuximab